Double blind comparative randomized study to evaluate efficacy and safety of CP-010, Homeopathy drug as compare to Magnesium Phosphoricum in the management of sub-acute and chronic painful conditions.â?? - Nil

Start Date16 Feb 2012

Sponsor / Collaborator-

CTRI/2012/02/002449 / CompletedNot Applicable

Homeopathic Drug Proving study to evaluate the clinical Symptoms of CP-010 in healthy volunteers.

Start Date04 Feb 2012

Sponsor / Collaborator-

100 Clinical Results associated with CP010

100 Translational Medicine associated with CP010

100 Patents (Medical) associated with CP010

Literatures (Medical) associated with CP010

01 Jan 2023·Journal of Innate ImmunityQ2 · MEDICINE

Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex

Q2 · MEDICINE

ArticleOA

Author: Wang, Yi ; Zhang, Yuchun ; Zelek, Wioleta M ; Johnson, Krista K ; Marquart, J Arnoud ; Ahasan, Muhammad ; Mei, Hailiang ; Ruizendaal, Patrick ; van Dijk, Marcus ; Michailidou, Iliana ; Gytz Olesen, Heidi ; Andersen, Gregers Rom ; Vreijling, Jeroen ; Baas, Frank ; Morgan, B Paul ; de Klein, Ferry ; Kuipers, Thomas B ; Fluiter, Kees

Damage and disease of nerves activates the complement system. We demonstrated that activation of the terminal pathway of the complement system leads to the formation of the membrane attack complex (MAC) and delays regeneration in the peripheral nervous system. Animals deficient in the complement component C6 showed improved recovery after neuronal trauma. Thus, inhibitors of the MAC might be of therapeutic use in neurological disease. Here, we describe the development, structure, mode of action, and properties of a novel therapeutic monoclonal antibody, CP010, against C6 that prevents formation of the MAC in vivo. The monoclonal antibody is humanized and specific for C6 and binds to an epitope in the FIM1-2 domain of human and primate C6 with sub-nanomolar affinity. Using biophysical and structural studies, we show that the anti-C6 antibody prevents the interaction between C6 and C5/C5b by blocking the C6 FIM1-2:C5 C345c axis. Systemic administration of the anti-C6 mAb caused complete depletion of free C6 in circulation in transgenic rats expressing human C6 and thereby inhibited MAC formation. The antibody prevented disease in experimental autoimmune myasthenia gravis and ameliorated relapse in chronic relapsing experimental autoimmune encephalomyelitis in human C6 transgenic rats. CP010 is a promising complement C6 inhibitor that prevents MAC formation. Systemic administration of this C6 monoclonal antibody has therapeutic potential in the treatment of neuronal disease.

100 Deals associated with CP010

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Injuries, Traumatic	Preclinical	-	Complement Pharma	-
Brain Injuries, Traumatic	Preclinical	-	Alexion Pharmaceuticals, Inc.	-
Brain Injuries, Traumatic	Preclinical	-	Regenesance BV	-
Guillain-Barre Syndrome	Preclinical	-	Regenesance BV	-
Guillain-Barre Syndrome	Preclinical	-	Complement Pharma	-
Guillain-Barre Syndrome	Preclinical	-	Alexion Pharmaceuticals, Inc.	-
Nerve Degeneration	Preclinical	-	Complement Pharma	-
Nerve Degeneration	Preclinical	-	Alexion Pharmaceuticals, Inc.	-
Nerve Degeneration	Preclinical	-	Regenesance BV	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CP010

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation